{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T20:19:19Z","timestamp":1772050759994,"version":"3.50.1"},"reference-count":83,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["seminoncol.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1053\/j.seminoncol.2016.11.011","type":"journal-article","created":{"date-parts":[[2016,11,17]],"date-time":"2016-11-17T08:00:27Z","timestamp":1479369627000},"page":"647-654","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["PI3K signaling pathway in normal B cells and indolent B-cell malignancies"],"prefix":"10.1053","volume":"43","author":[{"given":"Georgios","family":"Pongas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce D.","family":"Cheson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1053\/j.seminoncol.2016.11.011_bib1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1053\/j.seminoncol.2016.11.011_bib2","unstructured":"Gilead stops six trials adding idelalisib to other drugs. www.medscape.com. Accessed March 14, 2016"},{"issue":"55","key":"10.1053\/j.seminoncol.2016.11.011_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/82_2010_55","article-title":"Introduction","volume":"346","author":"Yuan","year":"2010","journal-title":"Phosphoinositide 3-kinase in health and disease"},{"issue":"1","key":"10.1053\/j.seminoncol.2016.11.011_bib4","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1146\/annurev-immunol-032712-095946","article-title":"Signaling by the phosphoinositide 3-kinase family in immune cells","volume":"31","author":"Okkenhaug","year":"2013","journal-title":"Ann Rev Immunol"},{"key":"10.1053\/j.seminoncol.2016.11.011_bib5","series-title":"Introduction. Phosphoinositide 3-kinase in health and disease","first-page":"1","author":"Yuan","year":"2010"},{"issue":"5","key":"10.1053\/j.seminoncol.2016.11.011_bib6","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.cell.2013.04.031","article-title":"RAS and RHO families of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms","volume":"153","author":"Fritsch","year":"2013","journal-title":"Cell"},{"issue":"5224","key":"10.1053\/j.seminoncol.2016.11.011_bib7","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1126\/science.7624799","article-title":"Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase","volume":"269","author":"Stoyanov","year":"1995","journal-title":"Science"},{"issue":"6","key":"10.1053\/j.seminoncol.2016.11.011_bib8","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ccr.2011.04.016","article-title":"Receptor tyrosine kinases and TLR\/IL1Rs unexpectedly activate myeloid cell PI3K\u03b3, a single convergent point promoting tumor inflammation and progression","volume":"19","author":"Schmid","year":"2011","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1053\/j.seminoncol.2016.11.011_bib9","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.tibs.2005.02.008","article-title":"Signalling by PI3K isoforms: insights from gene-targeted mice","volume":"30","author":"Vanhaesebroeck","year":"2005","journal-title":"Trends Biochem Sci"},{"issue":"6","key":"10.1053\/j.seminoncol.2016.11.011_bib10","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1084\/jem.20020805","article-title":"A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation","volume":"196","author":"Clayton","year":"2002","journal-title":"J Exp Med"},{"issue":"5583","key":"10.1053\/j.seminoncol.2016.11.011_bib11","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1126\/science.1073560","article-title":"Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice","volume":"297","author":"Okkenhaug","year":"2002","journal-title":"Science"},{"issue":"5455","key":"10.1053\/j.seminoncol.2016.11.011_bib12","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1126\/science.287.5455.1049","article-title":"Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation","volume":"287","author":"Hirsch","year":"2000","journal-title":"Science"},{"issue":"5455","key":"10.1053\/j.seminoncol.2016.11.011_bib13","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1126\/science.287.5455.1040","article-title":"Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration","volume":"287","author":"Sasaki","year":"2000","journal-title":"Science"},{"issue":"16","key":"10.1053\/j.seminoncol.2016.11.011_bib14","doi-asserted-by":"crossref","first-page":"10963","DOI":"10.1074\/jbc.274.16.10963","article-title":"Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase","volume":"274","author":"Bi","year":"1999","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1053\/j.seminoncol.2016.11.011_bib15","first-page":"169","article-title":"Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase","volume":"13","author":"Bi","year":"2002","journal-title":"Mamm Genome"},{"issue":"134","key":"10.1053\/j.seminoncol.2016.11.011_bib16","doi-asserted-by":"crossref","first-page":"ra60","DOI":"10.1126\/scisignal.2001104","article-title":"The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development","volume":"3","author":"Ramadani","year":"2010","journal-title":"Sci Signal"},{"issue":"5110","key":"10.1053\/j.seminoncol.2016.11.011_bib17","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1126\/science.7684160","article-title":"CD19 of B cells as a surrogate kinase insert region to bind phosphatidylinositol 3-kinase","volume":"260","author":"Tuveson","year":"1993","journal-title":"Science"},{"issue":"7","key":"10.1053\/j.seminoncol.2016.11.011_bib18","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.4049\/jimmunol.158.7.3062","article-title":"Membrane IgM-induced tyrosine phosphorylation of CD19 requires a CD19 domain that mediates association with components of the B cell antigen receptor complex","volume":"158","author":"Carter","year":"1997","journal-title":"J Immunol"},{"issue":"1","key":"10.1053\/j.seminoncol.2016.11.011_bib19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1084\/jem.173.1.55","article-title":"Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19","volume":"173","author":"Matsumoto","year":"1991","journal-title":"J Exp Med"},{"issue":"9","key":"10.1053\/j.seminoncol.2016.11.011_bib20","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.4049\/jimmunol.149.9.2841","article-title":"The CD19\/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules","volume":"149","author":"Bradbury","year":"1992","journal-title":"J Immunol"},{"issue":"7","key":"10.1053\/j.seminoncol.2016.11.011_bib21","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1002\/j.1460-2075.1993.tb05930.x","article-title":"Tyrosine phosphorylation of CD19 in pre-B and mature B cells","volume":"12","author":"Chalupny","year":"1993","journal-title":"EMBO J"},{"issue":"6538","key":"10.1053\/j.seminoncol.2016.11.011_bib22","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/376352a0","article-title":"Impairment of T-cell-dependent B-cell responses and B-l cell development in CD19-deficient mice","volume":"376","author":"Rickert","year":"1995","journal-title":"Nature"},{"issue":"6","key":"10.1053\/j.seminoncol.2016.11.011_bib23","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S1074-7613(00)00079-0","article-title":"BCAP: the tyrosine kinase substrate that connects B cell receptor to phosphoinositide 3-kinase activation","volume":"13","author":"Okada","year":"2000","journal-title":"Immunity"},{"issue":"2","key":"10.1053\/j.seminoncol.2016.11.011_bib24","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1182\/blood.V99.2.584","article-title":"Tyrosine phosphorylation of B-cell adaptor for phosphoinositide 3-kinase is required for Akt activation in response to CD19 engagement","volume":"99","author":"Inabe","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminoncol.2016.11.011_bib25","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood-2007-08-109769","article-title":"Regulation of B-cell development by BCAP and CD19 through their binding to phosphoinositide 3-kinase","volume":"111","author":"Aiba","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminoncol.2016.11.011_bib26","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1084\/jem.20060990","article-title":"BAFF controls B cell metabolic fitness through a PKC\u03b2- and Akt-dependent mechanism","volume":"203","author":"Patke","year":"2006","journal-title":"J Exp Med"},{"issue":"4","key":"10.1053\/j.seminoncol.2016.11.011_bib27","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.4049\/jimmunol.173.4.2236","article-title":"Cutting edge: differential roles for phosphoinositide 3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homing","volume":"173","author":"Reif","year":"2004","journal-title":"J Immunol"},{"issue":"12","key":"10.1053\/j.seminoncol.2016.11.011_bib28","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","article-title":"Phosphatidylinositol 3-kinase-\u03b4 inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals","volume":"116","author":"Herman","year":"2010","journal-title":"Blood"},{"issue":"26","key":"10.1053\/j.seminoncol.2016.11.011_bib29","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1182\/blood-2014-11-610329","article-title":"The PI3K\/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the E\u00b5-TCL1 mouse model","volume":"125","author":"Blunt","year":"2015","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.11.011_bib30","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-16-1662","article-title":"The dual Syk\/JAK inhibitor cerdulatinib antagonises B-cell receptor and microenvironmental signaling in chronic lymphocytic leukemia","author":"Blunt","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1053\/j.seminoncol.2016.11.011_bib31","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminoncol.2016.11.011_bib32","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2002-10-3306","article-title":"ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile","volume":"101","author":"Wiestner","year":"2003","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminoncol.2016.11.011_bib33","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1084\/jem.20031074","article-title":"Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma","volume":"198","author":"Rosenwald","year":"2003","journal-title":"J Exp Med"},{"issue":"484","key":"10.1053\/j.seminoncol.2016.11.011_bib34","first-page":"123","article-title":"PI3K signaling in normal B cells and chronic lymphocytic leukemia (CLL)","volume":"393","author":"Okkenhaug","year":"2016","journal-title":"Curr Top Microbiol Immunol"},{"issue":"7415","key":"10.1053\/j.seminoncol.2016.11.011_bib35","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nature11309","article-title":"Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling","volume":"489","author":"D\u00fchren-von Minden","year":"2012","journal-title":"Nature"},{"issue":"6160","key":"10.1053\/j.seminoncol.2016.11.011_bib36","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1126\/science.1243292","article-title":"Phosphoinositide 3-kinase \u03b4 gene mutation predisposes to respiratory infection and airway damage","volume":"342","author":"Angulo","year":"2013","journal-title":"Science"},{"issue":"3","key":"10.1053\/j.seminoncol.2016.11.011_bib37","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s10875-014-0012-9","article-title":"Mutations in PIK3CD can cause hyper IgM syndrome (HIGM) associated with increased cancer susceptibility","volume":"34","author":"Crank","year":"2014","journal-title":"J Clin Immunol"},{"issue":"1","key":"10.1053\/j.seminoncol.2016.11.011_bib38","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/ni.2771","article-title":"Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110\u03b4 result in T cell senescence and human immunodeficiency","volume":"15","author":"Lucas","year":"2014","journal-title":"Nat Immunol"},{"issue":"13","key":"10.1053\/j.seminoncol.2016.11.011_bib39","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1084\/jem.20141759","article-title":"Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K","volume":"211","author":"Lucas","year":"2014","journal-title":"J Exp Med"},{"issue":"13","key":"10.1053\/j.seminoncol.2016.11.011_bib40","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3\u2032-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia","volume":"118","author":"Hoellenriegel","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.11.011_bib41","unstructured":"ClinicalTrials.gov. Study of efficacy of CDZ173 in patients with APDS\/PASLI (NCT02435173). National Institute of Health NIH. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02435173?term=PIK3CD&rank=8. Accessed September 13, 2016."},{"key":"10.1053\/j.seminoncol.2016.11.011_bib42","unstructured":"ClinicalTrials.gov. Safety, pharmacokinetic (PK) and pharmacodynamic (PD) study of repeat doses of inhaled GSK2269557 in patients with APDS\/PASLI (NCT02593539). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02593539. Accessed September 25, 2016."},{"issue":"12","key":"10.1053\/j.seminoncol.2016.11.011_bib43","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.7150\/jca.11279","article-title":"The expression of CD9 and PIK3CD is associated with prognosis of follicular lymphoma","volume":"6","author":"Dong","year":"2015","journal-title":"J Cancer"},{"issue":"14","key":"10.1053\/j.seminoncol.2016.11.011_bib44","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1158\/1078-0432.CCR-11-2342","article-title":"Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia","volume":"18","author":"Brown","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1053\/j.seminoncol.2016.11.011_bib45","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1053\/j.seminoncol.2016.11.011_bib46","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2016.11.011_bib47","unstructured":"US Food and Drug Administration. FDA approves Zydelig for three types of blood cancers. Available at: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm406387.htm. Accessed September 5, 2016."},{"issue":"3","key":"10.1053\/j.seminoncol.2016.11.011_bib48","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.ccr.2014.02.005","article-title":"Angiocrine factors deployed by tumor vascular niche induce B cell lymphoma invasiveness and chemoresistance","volume":"25","author":"Cao","year":"2014","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1053\/j.seminoncol.2016.11.011_bib49","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1084\/jem.20121571","article-title":"Inhibition of the p110\u03b1 isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis","volume":"210","author":"Soler","year":"2013","journal-title":"J Exp Med"},{"key":"10.1053\/j.seminoncol.2016.11.011_bib50","unstructured":"ClinicalTrials.gov. Phase III copanlisib in rituximab-refractory iNHL (NCT02369016). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02369016. Accessed September 25, 2016."},{"issue":"1","key":"10.1053\/j.seminoncol.2016.11.011_bib51","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.seminoncol.2016.11.011_bib52","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1182\/blood-2007-05-089409","article-title":"Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia","volume":"110","author":"B\u00fcrkle","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.11.011_bib53","article-title":"Unexpected and serious toxicity observed with combined idelalisib, lenalidomide and rituximab in relapsed\/refractory B cell lymphomas: Alliance A051201 and A051202","author":"Smith","year":"2014","journal-title":"ASH Meeting Abstracts"},{"issue":"21","key":"10.1053\/j.seminoncol.2016.11.011_bib54","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1182\/blood-2015-03-633156","article-title":"Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed\/refractory indolent lymphoma","volume":"125","author":"Cheah","year":"2015","journal-title":"Blood"},{"issue":"20","key":"10.1053\/j.seminoncol.2016.11.011_bib55","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1182\/blood-2015-12-683516","article-title":"Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL","volume":"127","author":"Barr","year":"2016","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.11.011_bib56","doi-asserted-by":"crossref","unstructured":"Sehn LH, Hallek M, Jurczak W, Brown J. A retrospective analysis of Pneumocystis jirovecii pneumonia infection in patients receiving idelalisib in clinical trials. ASH Meeting Abstracts 2016.","DOI":"10.1182\/blood.V128.22.3705.3705"},{"issue":"10","key":"10.1053\/j.seminoncol.2016.11.011_bib57","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","article-title":"Management of adverse events associated with idelalisib treatment: expert panel opinion","volume":"56","author":"Coutre","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1053\/j.seminoncol.2016.11.011_bib58","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1097\/PAS.0000000000000522","article-title":"Idelalisib-associated colitis: histologic findings in 14 patients","volume":"39","author":"Weidner","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1053\/j.seminoncol.2016.11.011_bib59","doi-asserted-by":"crossref","unstructured":"Yeung C, Hockenbery D, Westerhoff M. Pathology results of tissue biopsy during idelalisib-associated diarrhea\/colitis. ASH Meeting Abstracts 2016.","DOI":"10.1182\/blood.V128.22.4391.4391"},{"issue":"3","key":"10.1053\/j.seminoncol.2016.11.011_bib60","first-page":"673","article-title":"Identification of a phosphoinositide 3-kinase (pi-3k) p110delta (pik3cd) deficient individual","volume":"33","author":"Zhang","year":"2013","journal-title":"J Clin Immunol"},{"issue":"5583","key":"10.1053\/j.seminoncol.2016.11.011_bib61","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1126\/science.1073560","article-title":"Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice","volume":"297","author":"Okkenhaug","year":"2002","journal-title":"Science"},{"key":"10.1053\/j.seminoncol.2016.11.011_bib62","series-title":"Full prescribing information","year":"2014"},{"issue":"2","key":"10.1053\/j.seminoncol.2016.11.011_bib63","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1182\/blood-2016-03-707133","article-title":"Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity","volume":"128","author":"Lampson","year":"2016","journal-title":"Blood"},{"issue":"14 Suppl","key":"10.1053\/j.seminoncol.2016.11.011_bib64","article-title":"Differential regulation of human T-cells by TGR-1202, a novel PI3K\u03b4 inhibitor","volume":"76","author":"Maharaj","year":"2016","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2016.11.011_bib65","doi-asserted-by":"crossref","unstructured":"O\u05f3Connor O.A., Flinn IW, Patel MR, et al. TGR-1202, a novel once daily PI3K-delta inhibitor, demonstrates clinical activity with a favorable safety profile in patients with CLL and B-cell lymphoma. ASH Meeting Abstracts 2015","DOI":"10.1182\/blood.V126.23.4154.4154"},{"issue":"15 suppl","key":"10.1053\/j.seminoncol.2016.11.011_bib66","first-page":"7512","article-title":"Long-term follow-up of the PI3K{delta} inhibitor TGR-1202 to demonstrate a differentiated safety profile and high response rates in CLL and NHL: integrated-analysis of TGR-1202 monotherapy and combined with ublituximab","volume":"34","author":"Burris","year":"2016","journal-title":"ASCO Meeting Abstracts"},{"issue":"7587","key":"10.1053\/j.seminoncol.2016.11.011_bib67","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nature16486","article-title":"Graded Foxo1 activity in Treg cells differentiates tumour immunity from spontaneous autoimmunity","volume":"529","author":"Luo","year":"2016","journal-title":"Nature"},{"issue":"7","key":"10.1053\/j.seminoncol.2016.11.011_bib68","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/ni.3441","article-title":"BACH2 regulates CD8(+) T cell differentiation by controlling access of AP-1 factors to enhancers","volume":"17","author":"Roychoudhuri","year":"2016","journal-title":"Nat Immunol"},{"issue":"2","key":"10.1053\/j.seminoncol.2016.11.011_bib69","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1172\/JCI82884","article-title":"The transcription factor BACH2 promotes tumor immunosuppression","volume":"126","author":"Roychoudhuri","year":"2016","journal-title":"J Clin Invest"},{"issue":"22","key":"10.1053\/j.seminoncol.2016.11.011_bib70","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","article-title":"A phase 1 study of the PI3K\u03b4 inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"123","author":"Kahl","year":"2014","journal-title":"Blood"},{"issue":"25","key":"10.1053\/j.seminoncol.2016.11.011_bib71","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1182\/blood-2015-03-630947","article-title":"A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia","volume":"126","author":"O\u05f3Brien","year":"2015","journal-title":"Blood"},{"issue":"15 suppl","key":"10.1053\/j.seminoncol.2016.11.011_bib72","first-page":"7514","article-title":"Results of a randomized, double-blind placebo-controlled phase 3 study evaluating idelalisib in combination with bendamustine and rituximab in patients with relapsed\/refractory CLL and adverse prognostic features","volume":"34","author":"Barrientos","year":"2016","journal-title":"ASCO Meeting Abstracts"},{"issue":"15 suppl","key":"10.1053\/j.seminoncol.2016.11.011_bib73","first-page":"7515","article-title":"Updated results of a phase III randomized, controlled study of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL)","volume":"34","author":"Jones","year":"2016","journal-title":"ASCO Meeting Abstracts"},{"issue":"15 suppl","key":"10.1053\/j.seminoncol.2016.11.011_bib74","first-page":"8529","article-title":"Idelalisib efficacy and safety in follicular lymphoma patients from a phase 2 study","volume":"33","author":"Salles","year":"2015","journal-title":"ASCO Meeting Abstracts"},{"issue":"15 suppl","key":"10.1053\/j.seminoncol.2016.11.011_bib75","first-page":"7011","article-title":"Long-term follow-up of a phase Ib trial of idelalisib (IDELA) in combination with chemoimmunotherapy (CIT) in patients (pts) with relapsed\/refractory (R\/R) CLL including pts with del17p\/TP53 mutation","volume":"33","author":"Barrientos","year":"2015","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1053\/j.seminoncol.2016.11.011_bib76","doi-asserted-by":"crossref","unstructured":"Davids MS, Kim HT, Nicotra A. TGR-1202 in combination with ibrutinib in patients with relapsed or refractory CLL or MCL: preliminary results of a multicenter phase I\/Ib study. ASH Meeting Abstracts 2016.","DOI":"10.1002\/hon.2437_39"},{"key":"10.1053\/j.seminoncol.2016.11.011_bib77","article-title":"Duvelisib (IPI-145), a PI3K-\u03b4,\u03b3 inhibitor, is clinically active in patients with relapsed\/refractory chronic lymphocytic leukemia","author":"O\u05f3Brien","year":"2014","journal-title":"ASH Meeting Abstracts"},{"key":"10.1053\/j.seminoncol.2016.11.011_bib78","article-title":"1218 Dynamo: a phase 2 study demonstrating the clinical activity of duvelisib in patients with relapsed refractory indolent non-Hodgkin lymphoma","author":"Flinn","year":"2016","journal-title":"ASH Meeting Abstracts"},{"key":"10.1053\/j.seminoncol.2016.11.011_bib79","article-title":"Combination trial of duvelisib (IPI-145) with bendamustine, rituximab, or bendamustine\/rituximab in patients with lymphoma or chronic lymphocytic leukemia","author":"Flinn","year":"2015","journal-title":"ASH Meeting Abstracts"},{"key":"10.1053\/j.seminoncol.2016.11.011_bib80","article-title":"Preliminary results of a phase Ib study of duvelisib in combination with FCR (dFCR) in previously untreated, younger patients with CLL","author":"Davids","year":"2015","journal-title":"ASH Meeting Abstracts"},{"key":"10.1053\/j.seminoncol.2016.11.011_bib81","doi-asserted-by":"crossref","unstructured":"Casulo C, Sancho J-M, Eygen KV. Contempo: Preliminary results in first-line treatment of follicular lymphoma with the oral dual PI3K-\u03b4,\u03b3 inhibitor, duvelisib, in combination with rituximab or obinutuzumab. ASH Meeting Abstracts 2016.","DOI":"10.1182\/blood.V128.22.2979.2979"},{"key":"10.1053\/j.seminoncol.2016.11.011_bib82","article-title":"Phase 2A study of copanlisib, a novel PI3K inhibitor, in patients with indolent lymphoma","author":"Dreyling","year":"2014","journal-title":"ASH Meeting Abstracts"},{"issue":"23","key":"10.1053\/j.seminoncol.2016.11.011_bib83","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1182\/blood.V126.23.3935.3935","article-title":"Results of the mantle cell lymphoma subset from a phase 2a study of copanlisib, a novel PI3K inhibitor, in patients with indolent and aggressive lymphoma","volume":"126","author":"Cunningham","year":"2015","journal-title":"Blood"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775416301208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775416301208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T23:24:29Z","timestamp":1692573869000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775416301208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":83,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0093775416301208"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2016.11.011","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PI3K signaling pathway in normal B cells and indolent B-cell malignancies","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2016.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}